Is pulmonary arterial hypertension associated with interferon-β therapy for multiple sclerosis reversible? A case study to explore the complexity. Issue 1 (16th March 2020)

• Record Type: Journal Article
• Authors: Anthi, Anastasia; Stagaki, Eleni; Rallidis, Loukianos; Konstantonis, Dimitrios; Evangelopoulos, Maria-Eleftheria; Voumvourakis, Konstantinos; Armaganidis, Apostolos; Orfanos, Stylianos E.
• Is Part Of: ERJ open research. Volume 6:Issue 1(2020)
• Publication Date: 2020-03-16
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; Respiration; Respiratory organs -- Diseases; Respiratory organs -- Diseases -- Treatment; Respiratory Tract Diseases; Electronic journals; Fulltext; Internet Resources; Periodicals; Periodical; 616.2005
• DOI: 10.1183/23120541.00328-2019
• Languages: English
• ISSNs: 2312-0541

Abstract

Interferon (IFN)-β has been classified as a drug that is possibly associated with development of pulmonary arterial hypertension (PAH), a devastating disease that can lead to right heart failure and premature death [1]. The possible causal relationship between interferon-β exposure and pulmonary arterial hypertension development requires close follow-up of patients on treatment with interferon-β http://bit.ly/2OPGSVP